Can we predict and prevent adult morbidity in males with childhood-onset growth hormone deficiency?

In order to achieve an optimal quality of life and minimize morbidity in adulthood, the therapeutic management of patients with childhood-onset growth hormone deficiency (GHD) should follow strict guidelines. Optimal final height should be obtained by the early diagnosis of GHD and subsequent adequate growth hormone (GH) dosing and duration of treatment. Moreover, particularly in males with associated gonadotrophin deficiency, the psychosexual maladjustment could be prevented by the earlier induction of puberty, completion of the male phenotype and testicular stimulation with gonadotrophins or luteinizing hormone-releasing hormone. Finally, a satisfactory peak bone mass could be attained by continuation of GH treatment for some years after cessation of linear growth.